Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Feb 15, 2021 10:59am
275 Views
Post# 32567984

The Katniss Everdeen Effect ...

The Katniss Everdeen Effect ...Everything they are doing is to ramp up our value in USA/Europe/Japan (IMO).

4 considerations I believe are at the top of mind for management ...
1.  Get OTENA into Phase 3.
2.  Speed up 352 to market (filing for fast-track which will add a step-function increase in value).
3.  Speed up 340 (or similar) to market - maybe COVID trials was the doorway  (potentially add a step-function increase in value).
4.  Speed up new drug development - proof of a real mechanism to their drug development capabilities on the gaseous mediator side to add a step-function increase in value (hoping Aspirin was the first (maybe not), IBD was the second and then, one more valuable drug to show we have quick iterations down pat ... maybe Alzheimer's or Parkinsons (likely will be the same drug for both as we're looking to slow down the effects of aging on brain cells and I'm guessing that fits the bill for improved brain health.

Then ...

You have the "Katniss" effect ... moving us from a perception of weakness, into a positions of undeniable strength ... to make us look DESIRABLE.

I believe something like this would bring us the optimal pay-day ... should a company want to buy us.  I don't think ATE accepts anything from the large market players (USA/Europe/Japan) until we are in the most desirable position we can be.  That is worth the wait in my opinion.

All in my opinion.
<< Previous
Bullboard Posts
Next >>